Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.

  title={Clinical pharmacology and toxicity of 4'-O-tetrahydropyranyladriamycin.},
  author={Antonius A. Miller and Carl Gottfried Schmidt},
  journal={Cancer research},
  volume={47 5},
The clinical pharmacology and toxicity of a novel anthracycline derivative, 4'-O-tetrahydropyranyladriamycin (THP-adriamycin), was investigated in patients with advanced malignant diseases. The starting dose was 30 mg/m2 which was escalated by increments of 10 mg/m2. Twelve patients with a median age of 42 (range, 19-69) years and a median Eastern Cooperative Oncology Group performance score of 2 (range, 1-2) were entered into the study. The diagnoses included four testicular cancers, two… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 10 extracted citations

Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 1995
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…